← All trials
NCT02169310
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 18, 2014
- Primary completion
- Dec 31, 2025
- Completion date
- Dec 31, 2026
- First posted
- Jun 23, 2014
- Last posted
- Dec 19, 2023
- Enrollment
- 80
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- National Institute of Neurological Disorders and Stroke (NINDS)Lead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)Overall official - principal investigator
- Uniformed Services University of the Health SciencesCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.